Zevra Therapeutics (ZVRA) Raw Materials (2023 - 2024)

Zevra Therapeutics (ZVRA) reported Raw Materials of $4.5 million for Q3 2024, down 5.66% quarter-over-quarter from $4.8 million in Q2 2024.

Zevra Therapeutics (ZVRA) Raw Materials (2023 - 2024) Analysis & Trends

Zevra Therapeutics has reported Raw Materials for 2 years, with the latest figure at $4.5 million in Q3 2024.

For the quarter ending Q3 2024, Raw Materials changed N/A year-over-year to $4.5 million; the trailing twelve-month figure through Sep 2024 stood at $4.5 million (changed N/A YoY), and the FY2023 full-year result was $2.9 million, changed N/A from the prior year.
Raw Materials for Q3 2024 stood at $4.5 million, down from $4.8 million in the prior quarter.
The five-year high for Raw Materials was $4.8 million in Q2 2024, with the low at $2.9 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn
9	Abivax	94.37 Bn	94.37 Bn	-
10	Zevra Therapeutics	704.96 Mn	504.34 Mn	34.30 Mn

Download Data